tbuckley/cabot-search huggingface dataset:
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
Authors: Tala Shekarian, Eva Sivado, Anne-Catherine Jallas, Stéphane Depil, Janice Kielbassa, Isabelle Janoueix-Lerosey, Gregor Hutter, Nadège Goutagny, Christophe Bergeron, Alain Viari, Sandrine Valsesia-Wittmann, Christophe Caux, Aurélien Marabelle
Journal: Science Translational Medicine (2019)

Although immune checkpoint-targeted therapies are currently revolutionizing cancer care, only a minority of patients develop durable objective responses to anti-PD-1, PD-L1, and CTLA-4 therapy. Therefore, new therapeutic interventions are needed to increase the immunogenicity of tumors and overcome the resistance to these immunotherapies. Oncolytic properties of common viruses can be exploited for the priming of antitumor immunity, and such oncolytic viruses are currently in active clinical development in combination with immune checkpoint-targeted therapies. However, the routine implementation of these therapies is limited by their manufacturing constraints, the risk of exposure of clinical staff, and the ongoing regulations on genetically modified organisms. We sought to determine whether anti-infectious disease vaccines could be used as a commercially available source of immunostimulatory agents for cancer immunotherapy. We found that rotavirus vaccines have both immunostimulatory and oncolytic properties. In vitro, they can directly kill cancer cells with features of immunogenic cell death. In vivo, intratumoral rotavirus therapy has antitumor effects that are dependent on the immune system. In several immunocompetent murine tumor models, intratumoral rotavirus overcomes resistance to and synergizes with immune checkpoint-targeted therapy. Heat- and UV-inactivated rotavirus lost their oncolytic activity but kept their synergy with immune checkpoint-targeted antibodies through the up-regulation of the double-stranded RNA receptor retinoic acid-induced gene 1 (RIG-I). Rotavirus vaccines are clinical-grade products used in pediatric and adult populations. Therefore, in situ immunization strategies with intratumoral-attenuated rotavirus could be implemented quickly in the clinic.
P1.18-09 Trimodal Treatment of Locally Advanced Non-Small Cell Lung Cancer: Model-Based Comparison with Chemoradiation Only
Authors: M. Strange, I. Vogelius, L. Nygaard, M. Pøhl, J. Ravn, T. Lacoppidan, R. Petersen, G. Persson
Journal: Journal of Thoracic Oncology (2019)
P1.01-114 A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy
Authors: T. Leal, J. Lang, J. Schehr, K. Schneider, D. Wheeler, J. Malhotra, E. Bertino, J. Eickhoff, A. Traynor
Journal: Journal of Thoracic Oncology (2019)
EP1.04-30 RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study
Authors: F. García Martínez, M. Fernández-Velilla Peña, P. Cruz Castellanos, J. De Castro Carpeno, A. Pertejo, I. Torres Sánchez
Journal: Journal of Thoracic Oncology (2019)
P2.17-39 Relationship Between EGFR Mutation and Pathological Differentiation in Patients with Clinical Stage IA Lung Adenocarcinoma
Authors: J. Osawa, Y. Shimada, S. Maehara, H. Masaru, M. Kakihana, N. Kajiwara, T. Ohira, N. Ikeda
Journal: Journal of Thoracic Oncology (2019)
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Authors: Nagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, Eloisi Caldas-Lopes, Blesida Punzalan, Suhasini Joshi, Alexander Bolaender, Mohammad M. Uddin, Anna Rodina, Pengrong Yan, Anson Ku, Thomas Ku, Smit K. Shah, Serge Lyashchenko, Eva Burnazi, Tai Wang, Nicolas Lecomte, Yelena Janjigian, Anas Younes, Connie W. Batlevi, Monica L. Guzman, Gail J. Roboz, Jacek Koziorowski, Pat Zanzonico, Mary L. Alpaugh, Adriana Corben, Shanu Modi, Larry Norton, Steven M. Larson, Jason S. Lewis, Gabriela Chiosis, John F. Gerecitano, Mark P.S. Dunphy
Journal: Cancer Cell (2019)
Phase I/II multisite trial of optimally dosed clofarabine and low‐dose TBI for hematopoietic cell transplantation in acute myeloid leukemia
Authors: Elizabeth F. Krakow, Boglarka Gyurkocza, Barry E. Storer, Thomas R. Chauncey, Jeannine S. McCune, Jerald P. Radich, Michelle E. Bouvier, Elihu H. Estey, Rainer Storb, David G Maloney, Brenda M. Sandmaier
Journal: American Journal of Hematology (2019)

Abstract Clofarabine is an immunosuppressive purine nucleoside analog that may have better anti‐leukemic activity than fludarabine. We performed a prospective phase I/II multisite trial of clofarabine with 2 Gy total body irradiation as non‐myeloablative conditioning for allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia who were unfit for more intense regimens. Our main objective was to improve the 6‐month relapse rate following non‐myeloablative conditioning, while maintaining historic rates of non‐relapse mortality (NRM) and engraftment. Forty‐four patients, 53 to 74 (median: 69) years, were treated with clofarabine at 150 to 250 mg/m 2 , of whom 36 were treated at the maximum protocol‐specified dose. One patient developed multifactorial acute kidney injury and another developed multiorgan failure, but no other grade 3 to 5 non‐hematologic toxicities were observed. All patients fully engrafted. The 6‐month relapse rate was 16% (95% CI, 5%‐27%) among all patients and 14% (95% CI, 3%‐26%) among high‐risk patients treated at the maximum dose, meeting the pre‐specified primary efficacy endpoint. Overall survival was 55% (95% CI, 40%‐70%) and leukemia‐free survival was 52% (95% CI, 37%‐67%) at 2 years. Compared to a historical high‐risk cohort treated with the combination of fludarabine at 90 mg/m 2 and 2 Gy TBI, protocol patients treated with the clofarabine‐TBI regimen had lower rates of overall mortality (HR of 0.50, 95% CI, 0.28‐0.91), disease progression or death (HR 0.48, 95% CI, 0.27‐0.85), and morphologic relapse (HR 0.30, 95% CI, 0.13‐0.69), and comparable NRM (HR 0.85, 95% CI 0.36‐2.00). The combination of clofarabine with TBI warrants further investigation in patients with high‐risk AML.
EP1.15-29 Real World Characterization and Treatment of Patients with Thymic Carcinoma: Lessons from a Latin-American Study (CLICaP-LATimus)
Authors: L. Mas, A. Patané, O.G. Arrieta, T. Soria, A.F. Cardona, C. Martin, A. Ruiz-Patiño, L.L. Rojas, R. Ruiz, P. Rioja, S. Lozano, Z.L. Zatarain Barrón, M. Corassa, H. Freitas, V. Cordeiro De Lima, L. Corrales, C. Sotelo, J. Rodriguez, L. Ricaurte, J. Ávila, M. Bravo, D. Mayorga, P. Archila, J. Otero, H. Carranza, C. Vargas, R. Rosell, J. Remon
Journal: Journal of Thoracic Oncology (2019)
Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients
Authors: Amy Kunchok, John J. Chen, Andrew McKeon, John R. Mills, Eoin P. Flanagan, Sean J. Pittock
Journal: JAMA Neurology (2019)

This study characterizes the frequency and sex ratio of positive test results for myelin oligodendrocyte glycoprotein–IgG and aquaporin-4–IgG in adult and pediatric patient populations in a single center.
Brown Adipose Crosstalk in Tissue Plasticity and Human Metabolism
Authors: Camilla Scheele, Christian Wolfrum
Journal: Endocrine Reviews (2019)

Abstract Infants rely on brown adipose tissue (BAT) as a primary source of thermogenesis. In some adult humans, residuals of brown adipose tissue are adjacent to the central nervous system and acute activation increases metabolic rate. Brown adipose tissue (BAT) recruitment occurs during cold acclimation and includes secretion of factors, known as batokines, which target several different cell types within BAT, and promote adipogenesis, angiogenesis, immune cell interactions, and neurite outgrowth. All these processes seem to act in concert to promote an adapted BAT. Recent studies have also provided exciting data on whole body metabolic regulation with a broad spectrum of mechanisms involving BAT crosstalk with liver, skeletal muscle, and gut as well as the central nervous system. These widespread interactions might reflect the property of BAT of switching between an active thermogenic state where energy is highly consumed and drained from the circulation, and the passive thermoneutral state, where energy consumption is turned off. (Endocrine Reviews 41: XXX – XXX, 2020)
The long shadow post-tuberculosis
Authors: Brian Allwood, Marieke van der Zalm, Goodman Makanda, Kevin Mortimer, Amaral Andre F.S., Egere Uzochukwu, Evans Denise, Gray Diane, Hoddinott Graeme, Ivanova Olena, Jones Rupert, Marx Florian M., Meghji Jamilah, Mpagama Stellah, van Kampen Sanne, Rachow Andrea, Schoeman Ingrid, Stek Cari, von Delft Dalene, Walker Naomi, Wallis Robert
Journal: The Lancet Infectious Diseases (2019)
P1.16-35 The Prognostic Impact of Sarcopenia on the Clinical Outcome of Thoracic Surgery for Non-Small Cell Lung Cancer in Elderly Patients
Authors: A. Miura, J. Soh, S. Miyauchi, K. Araki, K. Nakata, K. Namba, K. Suzawa, S. Otani, H. Yamamoto, M. Okazaki, S. Sugimoto, M. Yamane, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib
Authors: Paul G. Richardson, Arnon Nagler, Dina Ben-Yehuda, Ashraf Badros, Parameswaran Hari, Roman Hajek, Ivan Spicka, Hakan Kaya, Richard Le Blanc, Sung-Soo Yoon, Kihyun Kim, Joaquin Martinez-Lopez, Moshe Mittelman, Ofer Shpilberg, Elena Tothova, Jacob P. Laubach, Irene M. Ghobrial, Merav Leiba, Moshe E. Gatt, Peter Sportelli, Michael Chen, Kenneth C. Anderson
Journal: Blood (2013)
P1.04-43 PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-Small Cell Lung Cancer - Trial in Progress
Authors: T. Kordbacheh, E. Cheadle, C. Chan, C. Trigwell, E. Taylor, C. Hiley, K. Franks, C. Ralph, M. Hatton, A. Chaturvedi, P. Crosbie, M. Forster, C. Dive, C. Faivre-Finn, T. Illidge
Journal: Journal of Thoracic Oncology (2019)
P2.12-04 CLEPSIDRA: A Phase II Trial Combining Iadademstat with Platinum-Etoposide in Platinum-Sensitive Relapsed SCLC Patients
Authors: M. Ropacki, A. Navarro, T. Maes, S. Gutierrez, R. Bullock, C. Buesa
Journal: Journal of Thoracic Oncology (2019)
Flow Cytometry Based MRD Monitoring Is an Accurate Risk Stratification Tool in Acute T-Lymphoblastic Leukemia
Authors: Signe Modvig, Hans O Madsen, Sanna M. Siitonen, Susanne Rosthøj, Vesa Juvonen, Liv T. N. Osnes, Helen Vålerhaugen, Magnus Hultdin, M Marincevic, Reda Matuzeviciene, Mindaugas Stoskus, Aili Lilleorg, Nina Toft, Ólafur G. Jónsson, Kjeld Schmiegelow, Hanne Vibeke Marquart
Journal: Blood (2017)
P1.01-63 Impact of Prior Radiation Pneumonitis on Incidence of Immunotherapy Related Pneumonitis
Authors: M. Kier, M. Marmarelis, C. Davis, V. Jain, A. Berman, J. Bauml, A. Singh, C. Ciunci, C. Aggarwal, C. Langer, R. Cohen
Journal: Journal of Thoracic Oncology (2019)
P2.10-09 Environmental Pollution in the City of Mexico as a Risk Factor for Lung Cancer and Its Prognostic Impact
Authors: O. Macedo-Perez, I. Lyra Gonzalez, L. Bornstein, J. Castellanos, K. Campos-Peralta, E. Jimenez-Fuentes
Journal: Journal of Thoracic Oncology (2019)
Severe leptospirosis in non-tropical areas: a nationwide, multicentre, retrospective study in French ICUs
Authors: Arnaud-Félix Miailhe, Emmanuelle Mercier, Adel Maamar, Jean-Claude Lacherade, Aurélie Le Thuaut, Aurélie Gaultier, Pierre Asfar, Laurent Argaud, Antoine Ausseur, Adel Ben Salah, Vlad Botoc, Karim Chaoui, Julien Charpentier, Christophe Cracco, Nicolas De Prost, Marie-Line Eustache, Alexis Ferré, Elena Gauvin, Suzanne Goursaud, Maximilien Grall, Philippe Guiot, Maud Jonas, Fabien Lambiotte, Mickael Landais, Jérémie Lemarié, Olivier Lesieur, Claire Lhommet, Philippe Michel, Yannick Monseau, Sébastien Moschietto, Saad Nseir, David Osman, Jérome Pillot, Gaël Piton, Nicholas Sedillot, Michel Sirodot, Didier Thevenin, Lara Zafrani, Yoann Zerbib, Pascale Bourhy, Jean-Baptiste Lascarrou, Jean Reignier
Journal: Intensive Care Medicine (2019)
HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice
Authors: Pushpendra Goswami, Sam Salek, Tatyana Ionova, Esther Natalie Oliva, Adele K Fielding, Marina Karakantza, Saad Al-Ismail, Graham Collins, Stewart McConnell, Catherine Langton, Daniel Jennings, Roger Else, William J. Kell
Journal: Blood (2017)
Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia
Authors: Michaela Kotrova, Antonia Volland, Britta Kehden, Heiko Trautmann, Matthias Ritgen, Ralph Wäsch, Christoph Faul, Andreas Viardot, Stefan Schwartz, Claudia D. Baldus, Nicola Gökbuget, Monika Brüggemann
Journal: Leukemia (2019)
P1.01-70 Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy
Authors: S. Lau, L. Le, S.W.S. Chan, E. Smith, M. Ryan, M.C. Brown, K. Hueniken, L. Eng, D. Patel, R.Q. Chen, M. Sung, A. Zer, P. Bradbury, P. Ohashi, F. Shepherd, M. Tsao, N. Leighl, G. Liu, A. Sacher
Journal: Journal of Thoracic Oncology (2019)
The Human Costs of Medicare Fraud and Abuse
Authors: Joseph S. Ross
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
MA01.02 Lung Stereotactic Body Radiotherapy and Concurrent Immunotherapy: A Multi-Center Safety and Toxicity Analysis
Authors: S. Tian, J. Switchenko, P. Patel, J. Shelton, S. Kahn, R. Pillai, C. Steuer, T. Owonikoko, M. Behera, W. Curran, K. Higgins
Journal: Journal of Thoracic Oncology (2019)
hnRNP K: A Tumor Suppressor or Oncogene?
Authors: Miguel Gallardo, Hun Ju Lee, Carlos E. Bueso-Ramos, Xiaorui Zhang, Laura R. Pageon, Asha Multani, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, Joaquin Martinez-Lopez, Sean M. Post
Journal: Blood (2014)
Concomitant pemetrexed/carboplatin chemotherapy with 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in locally advanced non-small cell lung cancer in a Chinese population
Authors: S. Ma, Y. Xu, X. Yu
Journal: Journal of Clinical Oncology (2009)

e18502 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, as well as superior toxicity profile in advanced non-small cell lung cancer(NSCLC). Radiotherapy(RT) has been shown to improve survival of patients with locally advanced NSCLC when combined with other platin doublets. This phase II study of concomitant pemetrexed/carboplatin chemotherapy(CT) with 3-D conformal RT followed by pemetrexed/carboplatin consolidation CT in locally advanced NSCLC was designed to evaluate the efficacy and safety of this novel regimen. This report presents preliminary information of 10 patients who have completed treatment. Methods: 10 chemoradiation (CRT)-naive and stage IIIA or IIIB (not effusion) with KPS≥80 patients were included in this study between February 2008 and October 2008. Patients received pemetrexed 500 mg/m 2 , carboplatin AUC 5 CT repeated q3 weeks for 2 cycles concomitant with RT and 3 cycles of consolidation pemetrexed (500 mg/m 2 ) and carboplatin (AUC=5) q3 weeks. Median total dose of RT, without elective nodal irradiation, was 62 Gy (range: 60-66 Gy) with 2 Gy daily fractions. Results: 1 (10%) and 8 patients (80%) had a complete or partial response respectively, while 1 patient(10%) had progression of the disease(brain metastases). The overall response rate (90%,95% confidence interval (CI): 68%-97%) exceeded the goal per study design. After concomitant CRT, the main toxicity was neutropenia, with a median ANC nadir of 1.6, three patients had Grade 3 neutropenia, One patient had Grade 4 neutropenia. Grade 3 thrombocytopenia was seen in one patient, grade 3 esophagitis in one patient and grade 3 radiation pneumonitis in one patient. Consolidation CT was not administered to 3 patients- one due to the development of brain metastases during the first month after chemoradiation, one due to patient refusal and one due to grade 3 radiation pneumonitis. Conclusions: This preliminary data suggests that concomitant treatment was well tolerated, with promising activity and a significant improvement of QoL in a Chinese population with locally advanced NSCLC. No significant financial relationships to disclose.
DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression
Authors: David Spencer, David Russler-Germain, Nichole M Helton, Tamara L Lamprecht, Marwan Shinawi, Peter Westervelt, Jacqueline E. Payton, Robert S. Fulton, Richard K Wilson, Matthew J. Walter, Daniel C. Link, John F. DiPersio, Timothy J. Ley
Journal: Blood (2016)
MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI
Authors: M. Ahn, S. Park, S. Hong, J. Park, M.R. Park, H.A. Jung, J. Sun, S. Lee, J.S. Ahn, K. Park
Journal: Journal of Thoracic Oncology (2019)
Host-Derived IL-22 Limits Graft Versus Host Disease and Protects the Intestinal Stem Cell Niche
Authors: Alan M. Hanash, Jarrod A Dudakov, Guoqiang Hua, Lauren F. Young, Maggie O'connor, Robert R Jenq, Amanda M Holland, Odette M Smith, Chen Liu, Lynette Fouser, Richard Kolesnick, Bruce R. Blazar, Marcel Van Den Brink
Journal: Blood (2011)
A phase II evaluation of aerosolized GM-CSF (AGM-CSF) plus standard I-MAP/ GM-CSF/MAP/ surgery/ irradiation in the reduction of pulmonary metastases (P-METS) in soft tissue sarcoma (STS) patients (PTS)
Authors: S. H. Okuno, M. R. Mahoney, B. F. Kabat, R. M. Marks, W. J. Maples, T. J. Fitch, I. A. Petersen, C. P. Beauchamp, M. I. O’ Connor, F. H. Sim
Journal: Journal of Clinical Oncology (2007)

10058 Background: P-METs remain illusive with standard treatments for STS. AGM-CSF demonstrated tolerability with promising efficacy in reducing P-METS. We evaluated the 2-yr P-MET free rate in chemonaiive pts with extremity STS. Methods: ECOG PS 0/1 and Gr 3/4 primary STS of the limb girdle/extremities, were required. Treatment sequence: 2 cycles of IMAP (Ifosfamide, Mitomycin, Doxorubicin, Cisplatin) plus s.q. GM-CSF (preload d -6 to -3, d1–14); MAP (d0, 28) during irradiation (d1–35) plus AGM-CSF 250 mcg bid (d1–7, 15- 22, 28–35); surgery; post-op irradiation plus AGM-CSF 250 mcg bid (d1–7, 15–22, 28–35, 42–49). 6 of 35 pts with P-METS in ≤ 2 yrs implied lack of efficacy w.r.t. reducing P-METS. Results: 38 eligible pts were enrolled (20 male, median age 51 yrs, 24 PS 0). Median size of tumor 9 cm (2.3–26.7 cm).Location of tumors included: proximal extremity-16, distal extremity-11, and limb girdle-12. 79% received debulking surgery; 29 rendered disease-free. 38 pts are evaluable for toxicity (see table ). More common Gr 3+ events related to treatment appear below. 79% had Gr 4 neutropenia, despite s.q. GM-CSF. 6 pts have died, with 2.5 yrs median follow-up on survivors (range .4- 4.6). No treatment related fatalities occurred. 10 pts had P-METS ≤ 2 yrs. The estimated 2 yr P-MET free rate is 75% (95% CI 62–91). Conclusions: Although high, neutropenia was as expected. AGM-CSF failed to improve the 2 yr P-MET free rate in this group of STS pts. Other strategies need to be explored. Supported by NIH Grant CA15083–32 and Berlex Corporation. Max Severity (Gr 3+) [Table: see text] No significant financial relationships to disclose.
JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: B. Han, T. Chu, R. Zhong, H. Zhong, B. Zhang, W. Zhang, C. Shi, J. Qian, Y. Han
Journal: Journal of Thoracic Oncology (2019)
P2.01-92 Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC
Authors: E. Neninger, H. Caceres, K. Camacho, M. Hernandez, E. Santiesteban, C. Del Castillo, Y. Menendez, B. Gonzalez
Journal: Journal of Thoracic Oncology (2019)
JCSE01.14 Higher Prevalence of EGFR Mutations Significantly Correlates with Lower PD-L1 Expression in Chinese Lung Adenocarcinoma
Authors: S. Wen, Y. Jiang, J. Guo, X. Fan, X. Pan, Y. Dai, D. Chen, K. Wang, X. Dong, S. Zhang
Journal: Journal of Thoracic Oncology (2019)
P1.01-126 The Co-Occurring Genomic Landscape of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
Authors: B. Yuan, J. Zhao, C. Zhou, X. Wang, B. Zhu, M. Zhuo, C. Yi, H. Zhang, X. Dong, J. Feng, Y. Yang, W. Zhou, Z. Chen, S. Yang, Y. Zhang, X. Ai, K. Chen, X. Cui, D. Liu, W. Wu, C. Shi, L. Chang, J. Li, R. Chen, S. Yang
Journal: Journal of Thoracic Oncology (2019)
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
Authors: Rahul K Nayak, Jerry Avorn, Aaron S Kesselheim
Journal: BMJ (2019)

To determine the extent to which late stage development of new drugs relies on support from public funding.Cohort study.All new drugs containing one or more new molecular entities approved by the US Food and Drug Administration (FDA) between January 2008 and December 2017 via the new drug application pathway.Patents or drug development histories documenting late stage research contributions by a public sector research institution or a spin-off company, as well as each drug's regulatory approval pathway and first-in-class designation.Over the 10 year study period, the FDA approved 248 drugs containing one or more new molecular entities. Of these drugs, 48 (19%) had origins in publicly supported research and development and 14 (6%) originated in companies spun off from a publicly supported research program. Drugs in these groups were more likely to receive expedited FDA approval (68% v 47%, P=0.005) or be designated first in class (45% v 26%, P=0.007), indicating therapeutic importance.A review of the patents associated with new drugs approved over the past decade indicates that publicly supported research had a major role in the late stage development of at least one in four new drugs, either through direct funding of late stage research or through spin-off companies created from public sector research institutions. These findings could have implications for policy makers in determining fair prices and revenue flows for these products.
Treatment of Secondary Post-Transplant Engraftment Failure with Donor CD34+ Enriched, T-Cell Depleted Peripheral Blood Stem Cells Isolated By the Clinimacs® System
Authors: Paolo Caimi, Jane Reese, Merle Kolk, Robert Fox, Kari Eckmeyer, Erin Galloway, Gina Hoffman, Ehsan Malek, Leland Metheny, Ben K. Tomlinson, Richard Creger, Brenda W. Cooper, Hillard M Lazarus, Marcos de Lima
Journal: Blood (2017)
P1.01-52 Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Agulnik, G. Kasymjanova, D. Small, C. Pepe, L. Sakr, G. Chong, H. Wang, A. Papadakis, A. Spatz, V. Cohen
Journal: Journal of Thoracic Oncology (2019)